Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Grimes

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
International Journal of Molecular Sciences|February 15, 2022
Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance PathophysiologyFrank Greenway, Brian Loveridge, Richard M Grimes, et al.
Journal of Medicinal Chemistry|September 11, 2013
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomainsOlivier Mirguet, Romain Gosmini, Jérôme Toum, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moietiesXianfeng Li, Suoming Zhang, Yong-Kang Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronatesXianfeng Li, Yong-Kang Zhang, Yang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 proteaseXianfeng Li, Yong-Kang Zhang, Yang Liu, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
International Journal of Molecular Sciences|February 15, 2022
Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance PathophysiologyFrank Greenway, Brian Loveridge, Richard M Grimes, et al.
Journal of Medicinal Chemistry|September 11, 2013
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomainsOlivier Mirguet, Romain Gosmini, Jérôme Toum, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moietiesXianfeng Li, Suoming Zhang, Yong-Kang Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronatesXianfeng Li, Yong-Kang Zhang, Yang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 proteaseXianfeng Li, Yong-Kang Zhang, Yang Liu, et al.
Pageof 6